Grading — Assessing Tumour Cell Abnormality

Tumour grading is the laboratory classification of cancerous tissue based on microscopic appearance and differentiation. A pathologist examines a biopsy or surgical specimen, assessing architectural patterns, nuclear atypia, and mitotic figures. Tissues that closely resemble normal cells are described as well-differentiated or low grade. Conversely, cells displaying severe structural disorganisation, nuclear enlargement, and rapid replication are termed poorly differentiated, undifferentiated, or high grade.

Grading systems vary across different malignancies. Many solid tumours employ a three- or four-tier numerical scale (Grade 1 through Grade 3 or 4). In certain cancers, such as prostate adenocarcinoma, specialised scoring models like the Gleason system are used, whereas soft-tissue sarcomas often utilise the FNCLCC grading scheme. Regardless of the specific framework, grading categorises biological aggressiveness independently of how far the cancer has spread anatomically.

Understanding tumour grade is crucial because it directly influences your treatment pathway and surveillance plan. While cancer stage describes tumour size and physical location, the grade reveals its underlying biological behaviour. A low-grade tumour might be managed conservatively with active surveillance or localised surgery alone. In contrast, a high-grade tumour often warrants more aggressive intervention, such as adjuvant chemotherapy, targeted therapy, or radiotherapy, to destroy rapidly dividing cells. Recognising the grade helps patients appreciate why specific therapies are recommended and clarifies realistic expectations regarding disease progression and follow-up intervals.

Grading is assessed exclusively through histopathology. A pathologist examines tissue obtained via core biopsy, fine-needle aspiration cell blocks, or surgical resection. Tissue sections are stained, commonly using haematoxylin and eosin, to assess cell morphology and architectural patterns. Pathologists may also evaluate the mitotic count, sometimes aided by immunohistochemical biomarkers such as Ki-67, a protein indicating active cellular proliferation, to gauge how rapidly tumour cells are actively dividing and proliferating within the tissue.

Grading applies to most solid tumours, notably breast carcinoma, prostate cancer, brain tumours like astrocytomas, and soft-tissue sarcomas. It also features prominently in bladder cancer, renal cell carcinoma, and endometrial cancer. Notably, certain malignancies, such as some types of leukaemia and thyroid cancers, do not utilise standard histological grading systems because their management relies more heavily on cytogenetic analysis, molecular profiling, or anatomical staging rather than microscopic structural differentiation alone.

Grade heavily dictates therapeutic intensity. Low-grade tumours often respond well to surgery or local radiation alone, whereas high-grade tumours, being biologically more proliferative, are frequently sensitive to systemic chemotherapy that targets rapidly dividing cells. High-grade status may also necessitate adjuvant or neoadjuvant systemic therapies to prevent distant recurrence. Conversely, low-grade malignancies might qualify for watchful waiting, de-escalated therapy, or organ-sparing procedures, avoiding the toxicities of more intensive treatments.